{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019682","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.696184+00:00","generated_at":"2026-06-15T09:45:34.949336+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Design Therapeutics reports Q1 2023 net loss of $19.3M; cash $315.4M; Phase 1 MAD data for DT-216 expected in Q3 2023","bullets":["Net loss of $19.3M for Q1 2023; R&D expenses $15.7M, G&A expenses $5.9M.","Cash, equivalents and marketable securities $315.4M, expected to fund operations through 2025.","Initial Phase 1 multiple-ascending dose trial data for DT-216 in Friedreich ataxia expected Q3 2023.","IND submission for DT-168 eye drop for FECD on track for H2 2023; preclinical data presented at ARVO 2023.","IND submission for DM1 GeneTAC program on track for H2 2024; development candidate selection underway."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019682","json":"https://secwatch.observer/filing/0000950170-23-019682.json","markdown":"https://secwatch.observer/filing/0000950170-23-019682.md","text":"https://secwatch.observer/filing/0000950170-23-019682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/dsgn-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:45:34.949336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7905457ba10e75d3e4244dac3ff6a15d9cb8fb7","claim":"Design Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2023.","evidence_excerpt":"Research and development (R&D) expenses were $15.7 million for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c7905457ba10e75d3e4244dac3ff6a15d9cb8fb7","claim":"Design Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2023.","evidence_excerpt":"General and administrative (G&A) expenses were $5.9 million for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e4fbbc5c0abb98b70b91f7c7f0304fa11cd94c80","claim":"Design Therapeutics, Inc. reported for the three months ended March 31, 2023 results: net income Net loss was $19.3 million for the quarter ended March 31, 2023..","evidence_excerpt":"Net loss was $19.3 million for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023019682/0000950170-23-019682-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three months ended March 31, 2023"},{"label":"Net income","value":"Net loss was $19.3 million for the quarter ended March 31, 2023."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}